Skip to main content
Journal cover image

Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.

Publication ,  Journal Article
Amundsen, CL; Komesu, YM; Chermansky, C; Gregory, WT; Myers, DL; Honeycutt, EF; Vasavada, SP; Nguyen, JN; Wilson, TS; Harvie, HS; Wallace, D ...
Published in: Eur Urol
July 2018

BACKGROUND: Urgency urinary incontinence (UUI) is a chronic condition for which sacral neuromodulation (SNM) (InterStim/Medtronic) and onabotulinumtoxinA (BTX) (BotoxA/Allergan) are utilized. These therapies have not been compared over extended time. OBJECTIVE: To compare UUI episodes (UUIE) over 24 mo following SNM or BTX. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, open-label, randomized, extension trial (February 2012-July 2016) at nine US medical centers involving 386 women with ≥6 UUIE over 3 d inadequately managed by medications. Participants were clinical responders to treatment: ≥50% reduction in UUIEs after SNM placement or 1 mo post BTX. INTERVENTION: SNM (n=194) versus 200 U BTX (n=192). SNM reprogrammings occurred throughout the 24 mo. After 6 mo, two additional BTX injections were allowed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Primary outcome: change in mean daily UUIE over 24 mo. SECONDARY OUTCOMES: no UUIE, ≥75% and ≥50% UUIE reduction; Overactive Bladder Questionnaire Short Form; Urinary Distress Inventory short form; Incontinence Impact Questionnaire; Patient Global Impression of Improvement; Overactive Bladder Satisfaction of Treatment Questionnaire; and adverse events (AEs). Primary analysis used a linear mixed model. RESULTS AND LIMITATIONS: Outcome data were available for 260/298 (87%) clinical responders. No difference in decreased mean UUIE was found over 24 mo (-3.88 vs -3.50 episodes/d,95% confidence interval [CI]=-0.14-0.89; p=0.15), with no differences in UUI resolution, ≥75% or ≥50% UUIE reduction. BTX group maintained higher satisfaction (mean difference=-9.14, 95% CI=-14.38--3.90; p<0.001), treatment endorsement (mean difference=-12.16, 95% CI=-17.7--6.63; p<0.001) through 24 mo. Other secondary measures did not differ. Recurrent urinary tract infections (UTIs) were higher after BTX (24% vs 10%; p<0.01), 6% required intermittent catheterization post second injection. SNM revision and removals occurred in 3% and 9% patients, respectively. CONCLUSIONS: Both treatments offered sustainable UUI improvement, and higher BTX dosing had low clean intermittent catheterization rates, but with UTI risk. SNM revision/removal rates were low due to standardized lead placement with strict treatment response definitions. PATIENT SUMMARY: We compared a large group of US women with severe urgency urinary incontinence (UUI) who received sacral neuromodulation (InterStim) or onabotulinumtoxinA (Botox A) therapy during a 2-yr period. We found that both therapies had similar success in reducing UUI symptoms, and adverse events were low. However, women in the BotoxA group had higher satisfaction and endorsement with their treatment, but with a higher chance of a urinary tract infection. We conclude that both therapies offer sustained reduction in daily incontinence over 2 yr.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Eur Urol

DOI

EISSN

1873-7560

Publication Date

July 2018

Volume

74

Issue

1

Start / End Page

66 / 73

Location

Switzerland

Related Subject Headings

  • Urology & Nephrology
  • Urinary Tract Infections
  • Urinary Incontinence, Urge
  • Treatment Outcome
  • Sacrum
  • Neuromuscular Agents
  • Middle Aged
  • Humans
  • Female
  • Electrodes, Implanted
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Amundsen, C. L., Komesu, Y. M., Chermansky, C., Gregory, W. T., Myers, D. L., Honeycutt, E. F., … Pelvic Floor Disorders Network, . (2018). Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial. Eur Urol, 74(1), 66–73. https://doi.org/10.1016/j.eururo.2018.02.011
Amundsen, Cindy L., Yuko M. Komesu, Christopher Chermansky, W Thomas Gregory, Deborah L. Myers, Emily F. Honeycutt, Sandip P. Vasavada, et al. “Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.Eur Urol 74, no. 1 (July 2018): 66–73. https://doi.org/10.1016/j.eururo.2018.02.011.
Amundsen CL, Komesu YM, Chermansky C, Gregory WT, Myers DL, Honeycutt EF, et al. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial. Eur Urol. 2018 Jul;74(1):66–73.
Amundsen, Cindy L., et al. “Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.Eur Urol, vol. 74, no. 1, July 2018, pp. 66–73. Pubmed, doi:10.1016/j.eururo.2018.02.011.
Amundsen CL, Komesu YM, Chermansky C, Gregory WT, Myers DL, Honeycutt EF, Vasavada SP, Nguyen JN, Wilson TS, Harvie HS, Wallace D, Pelvic Floor Disorders Network. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial. Eur Urol. 2018 Jul;74(1):66–73.
Journal cover image

Published In

Eur Urol

DOI

EISSN

1873-7560

Publication Date

July 2018

Volume

74

Issue

1

Start / End Page

66 / 73

Location

Switzerland

Related Subject Headings

  • Urology & Nephrology
  • Urinary Tract Infections
  • Urinary Incontinence, Urge
  • Treatment Outcome
  • Sacrum
  • Neuromuscular Agents
  • Middle Aged
  • Humans
  • Female
  • Electrodes, Implanted